+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Forecast 2023-2030- Product Image
Global Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Forecast 2023-2030- Product Image
Sale

Global Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Forecast 2023-2030

  • PDF Icon

    Report

  • 181 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5896370
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antibody Drug Conjugate Market size was estimated at USD 4.85 billion in 2022, USD 5.60 billion in 2023, and is expected to grow at a CAGR of 16.03% to reach USD 15.96 billion by 2030.

The antibody drug conjugate (ADC) includes developing, manufacturing, and commercializing therapeutic molecules that combine monoclonal antibodies with cytotoxic agents. These hybrid compounds selectively target and eliminate cancer cells while minimizing toxicity to healthy tissue. ADCs are widely used in oncology due to their enhanced efficacy and reduced side effects compared to traditional chemotherapy. The continuous rise in cancer prevalence globally fuels the need for innovative therapies such as ADCs. However, the complexity of the manufacturing process for ADCs can be challenging, as they require multiple steps and stringent quality control measures to ensure product homogeneity and stability. Moreover, research is being conducted on applying ADC technologies to other diseases beyond oncology, including autoimmune disorders and infectious diseases, which is expected to encourage the utilization of ADCs by the end-use sectors worldwide.

Regional Insights

The antibody drug conjugates (ADCs) market is evolving in the Americas due to advancements in oncology and the need for targeted therapies. A robust research infrastructure and a favorable environment for innovation encourage growth of ADCs in the Americas. In the European Union (EU), centralized marketing authorization for ADCs is provided by the European Medicines Agency (EMA). The EU has observed several strategic collaborations to develop novel ADC therapy in recent years. The Middle East and Africa region presents untapped potential due to increasing healthcare expenditure and growing awareness of targeted therapies. Increasing R&D expenditure coupled with the prevalence of cancer are raising the need for ADCs in the APAC region. Additionally, introducing and utilizing advanced technologies for manufacturing ADCs is anticipated to increase their adoption by the end-use sectors across the globe.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Drug Conjugate Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Drug Conjugate Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Drug Conjugate Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ADC Therapeutics SA, Ambrx Biopharma Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BioNTech SE, Bristol-Myers Squibb Company, Byondis B.V., Celldex Therapeutics Inc., Creative Biolabs, Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Heidelberg Pharma AG, ImmunoGen, Inc., Innate Pharma SA, Innovent Biologics, Inc., Lonza Group Ltd., MacroGenics, Inc., MediLink Therapeutics, Merck KGaA, Mersana Therapeutics, Inc., Novartis AG, Oxford Biotherapeutics Limited, Pfizer, Inc., Pheon Therapeutics Ltd., Piramal Pharma Limited, Recipharm AB, Sanofi S.A., Sorrento Therapeutics, Inc., Tagworks Pharmaceuticals BV, Takeda Pharmaceutical Company Limited, Tubulis GmbH, and Zymeworks Inc.

Market Segmentation & Coverage

This research report categorizes the Antibody Drug Conjugate Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Mechanism of Action
    • CD30 Antibodies
    • ErbB2 Antibodies
  • Drugs
    • Adcetris
    • Blenrep
    • Enhertu
    • Kadcyla
    • Padcev
    • Trodelvy
  • Technology
    • Cleavable Linker
    • Linkerless
    • Non-Cleavable Linker
  • Indication
    • Blood Cancer
    • Breast Cancer
    • Lymphoma
    • Multiple Myeloma
    • Urothelial Cancer & Bladder Cancer
  • End User
    • Academic Research Institutes
    • Biopharmaceutical & Biotechnology Companies
    • Hospitals
    • Specialized Cancer Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • Alaska
        • California
        • Florida
        • Illinois
        • Massachusetts
        • Michigan
        • Montana
        • Nevada
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Antibody Drug Conjugate Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Drug Conjugate Market?
  3. What are the technology trends and regulatory frameworks in the Antibody Drug Conjugate Market?
  4. What is the market share of the leading vendors in the Antibody Drug Conjugate Market?
  5. Which modes and strategic moves are suitable for entering the Antibody Drug Conjugate Market?

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Antibody Drug Conjugate Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer worldwide
5.1.1.2. Growth in clinical trial activities and robust product pipeline
5.1.1.3. Government support and initiatives encouraging research on cancer
5.1.2. Restraints
5.1.2.1. High manufacturing cost of ADC and incidences of product recalls
5.1.3. Opportunities
5.1.3.1. Increasing investment in biopharma R&D and introduction of novel ADCs
5.1.3.2. Adoption of advanced technologies for developing ADC
5.1.4. Challenges
5.1.4.1. Complexity in manufacturing of ADCs
5.2. Market Segmentation Analysis
5.2.1. Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer
5.2.2. Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field
5.2.3. Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs
5.2.4. Indication: Rapid usage of ADCs for efficient treatment of breast cancer
5.2.5. End User: Emerging use of ADCs by academic research institutes for novel developments
5.3. Market Trend Analysis
5.3.1. Significant emphasis on securing approval for novel ADC drugs in the Americas
5.3.2. Cancer burden coupled with improving healthcare infrastructure in the APAC region
5.3.3. Supportive government initiatives for improved cancer research and treatment in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Antibody Drug Conjugate Market, by Mechanism of Action
6.1. Introduction
6.2. CD30 Antibodies
6.3. ErbB2 Antibodies
7. Antibody Drug Conjugate Market, by Drugs
7.1. Introduction
7.2. Adcetris
7.3. Blenrep
7.4. Enhertu
7.5. Kadcyla
7.6. Padcev
7.7. Trodelvy
8. Antibody Drug Conjugate Market, by Technology
8.1. Introduction
8.2. Cleavable Linker
8.3. Linkerless
8.4. Non-Cleavable Linker
9. Antibody Drug Conjugate Market, by Indication
9.1. Introduction
9.2. Blood Cancer
9.3. Breast Cancer
9.4. Lymphoma
9.5. Multiple Myeloma
9.6. Urothelial Cancer & Bladder Cancer
10. Antibody Drug Conjugate Market, by End User
10.1. Introduction
10.2. Academic Research Institutes
10.3. Biopharmaceutical & Biotechnology Companies
10.4. Hospitals
10.5. Specialized Cancer Centers
11. Americas Antibody Drug Conjugate Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Antibody Drug Conjugate Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Antibody Drug Conjugate Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. Merger & Acquisition
14.3.1.1. Pyxis Oncology Successfully Completes Acquisition of Apexigen
14.3.1.2. Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
14.3.1.3. Pfizer Invests USD 43 Billion to Battle Cancer
14.3.2. Agreement, Collaboration, & Partnership
14.3.2.1. BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
14.3.2.2. Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
14.3.2.3. BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
14.3.2.4. AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
14.3.3. Investment & Funding
14.3.3.1. Novartis-Backed Tagworks Raises USD 65 Million Series A to Further ADC, Click-to-Release Tech
14.3.4. Award, Recognition, & Expansion
14.3.4.1. Lonza to enhance commercial antibody-drug conjugate supply capacity
14.3.4.2. ENHERTU Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
14.3.4.3. U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Abbott Laboratories
15.1.2. AbbVie Inc.
15.1.3. ADC Therapeutics SA
15.1.4. Ambrx Biopharma Inc.
15.1.5. Amgen Inc.
15.1.6. Astellas Pharma Inc.
15.1.7. AstraZeneca PLC
15.1.8. Bayer AG
15.1.9. BioNTech SE
15.1.10. Bristol-Myers Squibb Company
15.1.11. Byondis B.V.
15.1.12. Celldex Therapeutics Inc.
15.1.13. Creative Biolabs, Inc.
15.1.14. Daiichi Sankyo Company, Limited
15.1.15. Eisai Co., Ltd.
15.1.16. F. Hoffmann-La Roche Ltd.
15.1.17. Gilead Sciences, Inc.
15.1.18. GlaxoSmithKline PLC
15.1.19. Heidelberg Pharma AG
15.1.20. ImmunoGen, Inc.
15.1.21. Innate Pharma SA
15.1.22. Innovent Biologics, Inc.
15.1.23. Lonza Group Ltd.
15.1.24. MacroGenics, Inc.
15.1.25. MediLink Therapeutics
15.1.26. Merck KGaA
15.1.27. Mersana Therapeutics, Inc.
15.1.28. Novartis AG
15.1.29. Oxford Biotherapeutics Limited
15.1.30. Pfizer, Inc.
15.1.31. Pheon Therapeutics Ltd.
15.1.32. Piramal Pharma Limited
15.1.33. Recipharm AB
15.1.34. Sanofi S.A.
15.1.35. Sorrento Therapeutics, Inc.
15.1.36. Tagworks Pharmaceuticals BV
15.1.37. Takeda Pharmaceutical Company Limited
15.1.38. Tubulis GmbH
15.1.39. Zymeworks Inc.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
List of Figures
FIGURE 1. ANTIBODY DRUG CONJUGATE MARKET RESEARCH PROCESS
FIGURE 2. ANTIBODY DRUG CONJUGATE MARKET SIZE, 2022 VS 2030
FIGURE 3. ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. ANTIBODY DRUG CONJUGATE MARKET DYNAMICS
FIGURE 7. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2022 VS 2030 (%)
FIGURE 8. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2022 VS 2030 (%)
FIGURE 10. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
FIGURE 12. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 14. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2022 VS 2030 (%)
FIGURE 16. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 20. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 25. ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 26. ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. ANTIBODY DRUG CONJUGATE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 6. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30 ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ERBB2 ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 9. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ADCETRIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLENREP, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENHERTU, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY KADCYLA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PADCEV, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRODELVY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 16. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKERLESS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE LINKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 20. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER & BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 26. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 47. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 48. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 49. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 53. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 54. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 74. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 75. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 79. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 80. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 81. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 89. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 90. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 91. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 119. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 120. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 134. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 135. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 136. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 140. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 141. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 145. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 146. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 147. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 150. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 151. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 152. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 156. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 157. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 165. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 166. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 167. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 180. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 181. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 182. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 185. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 186. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 188. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 190. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 191. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 192. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 193. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 210. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 211. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 212. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 213. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 225. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 226. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 240. ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2022
TABLE 241. ANTIBODY DRUG CONJUGATE MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • ADC Therapeutics SA
  • Ambrx Biopharma Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Byondis B.V.
  • Celldex Therapeutics Inc.
  • Creative Biolabs, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Heidelberg Pharma AG
  • ImmunoGen, Inc.
  • Innate Pharma SA
  • Innovent Biologics, Inc.
  • Lonza Group Ltd.
  • MacroGenics, Inc.
  • MediLink Therapeutics
  • Merck KGaA
  • Mersana Therapeutics, Inc.
  • Novartis AG
  • Oxford Biotherapeutics Limited
  • Pfizer, Inc.
  • Pheon Therapeutics Ltd.
  • Piramal Pharma Limited
  • Recipharm AB
  • Sanofi S.A.
  • Sorrento Therapeutics, Inc.
  • Tagworks Pharmaceuticals BV
  • Takeda Pharmaceutical Company Limited
  • Tubulis GmbH
  • Zymeworks Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages181
PublishedMarch 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 5.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.96 Billion
Compound Annual Growth Rate16.0%
Regions CoveredGlobal
No. of Companies Mentioned39

Related Topics

Related Reports

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology ({Type-Cleavable, Non-cleavable}), By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology ({Type-Cleavable, Non-cleavable}), By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 135 Pages
  • Global
From
Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key Geographical Regions (North America, Europe, and Asia-Pacific): Industry Trends and Global Forecasts, 2023-2035 - Product Image

Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key Geographical Regions (North America, Europe, and Asia-Pacific): Industry Trends and Global Forecasts, 2023-2035

  • Report
  • 716 Pages
  • Global
From
Global Antibody Drug Conjugates Contract Manufacturing Market by Linker (Cleavable, Non-cleavable), Condition (Breast Cancer, Lymphoma, Myeloma), End Use - Forecast 2024-2030 - Product Image

Global Antibody Drug Conjugates Contract Manufacturing Market by Linker (Cleavable, Non-cleavable), Condition (Breast Cancer, Lymphoma, Myeloma), End Use - Forecast 2024-2030

  • Report
  • 193 Pages
  • Global
From
Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, and Region - Forecast to 2028 - Product Image

Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, and Region - Forecast to 2028

  • Report
  • 273 Pages
  • Global
From
Antibody Drug Conjugates Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Technology, Application, Distribution Channel, and Geography - Product Image

Antibody Drug Conjugates Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Technology, Application, Distribution Channel, and Geography

  • Report
  • 178 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.